We are live on ! Find out more
CBAY

Cymabay Therapeutics
CBAY

Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

1 hedge funds and large institutions have $21.1K invested in Cymabay Therapeutics in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 198 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 200 → 1 (-199)

100% less funds holding in top 10

Funds holding in top 10: 10 → 0 (-10)

100% less capital invested

Capital invested by funds: $2.73B → $21.1K (-$2.73B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 198

Holders
1
Holders Change
-199
Holders Change %
-99.5%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
-10
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
198
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
-$262M
2
BlackRock
BlackRock
New York
-$227M
3
RCM
RA Capital Management
Massachusetts
-$164M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$149M
5
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$144M
Name Holding Trade Value Shares
Change 		Change in
Stake
Dimensional Fund Advisors
26
Dimensional Fund Advisors
Texas
– -$27.4M -1,161,964 Closed
AAA
27
Affinity Asset Advisors
New York
– -$25.8M -1,090,441 Closed
Northern Trust
28
Northern Trust
Illinois
– -$25.7M -1,090,087 Closed
EA
29
Emerald Advisers
Pennsylvania
– -$25.2M -1,068,661 Closed
Millennium Management
30
Millennium Management
New York
– -$21.8M -921,330 Closed
NHAS
31
Novo Holdings A/S
Denmark
– -$21.3M -900,000 Closed
EMFAT
32
Emerald Mutual Fund Advisers Trust
Pennsylvania
– -$20.7M -878,275 Closed
Charles Schwab
33
Charles Schwab
California
– -$20.2M -853,475 Closed
DCM
34
Driehaus Capital Management
Illinois
– -$19.9M -841,677 Closed
N
35
Nuveen
North Carolina
– -$17.8M -751,508 Closed
SVCM
36
Saturn V Capital Management
Texas
– -$17.7M -750,250 Closed
Assenagon Asset Management
37
Assenagon Asset Management
Luxembourg
– -$17.6M -746,353 Closed
Invesco
38
Invesco
Georgia
– -$17.2M -727,706 Closed
Westfield Capital Management
39
Westfield Capital Management
Massachusetts
– -$16.5M -700,056 Closed
Victory Capital Management
40
Victory Capital Management
Texas
– -$16.3M -689,603 Closed
D.E. Shaw & Co
41
D.E. Shaw & Co
New York
– -$15M -636,897 Closed
Goldman Sachs
42
Goldman Sachs
New York
– -$14.9M -630,735 Closed
MB
43
MPM BioImpact
Massachusetts
– -$14.4M -611,181 Closed
JFG
44
Jefferies Financial Group
New York
– -$13.8M -586,298 Closed
WP
45
Woodline Partners
California
– -$12.6M -532,002 Closed
HRCM
46
Hood River Capital Management
Florida
– -$12.3M -519,249 Closed
ACP
47
Acuta Capital Partners
California
– -$11.6M -492,155 Closed
ABG
48
Ally Bridge Group
New York
– -$11.6M -489,938 Closed
NIP
49
Nicholas Investment Partners
California
– -$10.3M -434,507 Closed
Bank of New York Mellon
50
Bank of New York Mellon
New York
– -$9.76M -413,279 Closed
1
2
3 4 5

CBAY Hedge Fund Activity: Q1 2024 in Review

1 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q1 2024, worth a combined $21.1K — down 100% from $2.73B a quarter earlier.

Sellers outnumbered buyers: 198 funds closed out of CBAY and 0 opened new positions — a net loss of 198 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $262M sold.

  • 1 institutional investor held Cymabay Therapeutics (CBAY) as of Q1 2024, down from 200 in Q4 2023.
  • Funds reported $21.1K of Cymabay Therapeutics stock for Q1 2024, down 100% quarter-over-quarter.
  • 0 funds opened new Cymabay Therapeutics positions in Q1 2024 and 198 closed out, a net change of -198 holders.
  • The largest Cymabay Therapeutics seller in Q1 2024 was Avoro Capital Advisors, an estimated $262M sold.

Based on aggregated 13F filings for Q1 2024.